Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia

Blood

Volumn 128, Issue 12, 2016, Pages 1625-1630

  Mahévas, Matthieu ^a   Gerfaud Valentin, Mathieu ^a,b   Moulis, Guillaume ^c,d   Terriou, Louis ^e   Audia, Sylvain ^f   Guenin, Sophie ^a   Le Guenno, Guillaume ^g   Salles, Gilles ^b   Lambotte, Olivier ^h,i,j   Limal, Nicolas ^a   Viallard, Jean François ^k   Cheze, Stephane ^l   Tomowiak, Cecile ^m   Royer, Bruno ⁿ   Neel, Antoine ^o   Debouverie, Odile ^m   Hot, Arnaud ^b   Durieu, Isabelle ^b   Perlat, Antoinette ^p   Cliquennois, Manuel ^q   Deteix, Clémence ^r   Michel, Marc ^a   Godeau, Bertrand ^a   more..

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DU BOCAGE   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ DIF   (France)

^j INSERM   (France)

^k HAUT LÉVÊQUE HOSPITAL   (France)

^l CHU CÔTE DE NACRE   (France)

^m POITIERS UNIVERSITY HOSPITAL   (France)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o NANTES UNIVERSITY HOSPITAL   (France)

^p SERVICE DE RHUMATOLOGIE   (France)

^q HÔPITAL SAINT VINCENT DE PAUL   (France)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DEXAMETHASONE; ELTROMBOPAG; MYCOPHENOLATE MOFETIL; RITUXIMAB; ROMIPLOSTIM; TACROLIMUS; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DISEASE DURATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; SEPSIS; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADVERSE EFFECTS; AGED; CASE CONTROL STUDY; CHILD; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG RESISTANCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHILD; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RITUXIMAB; SPLENECTOMY; SURVIVAL RATE; THROMBOPOIETIN; YOUNG ADULT;

EID: 84988697059     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-704734     Document Type: Article

References (24)

1. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
3. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104(4):956-960.
4. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
5. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-969.
6. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90(6):829-832.
7. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927-930.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
9. Bussel JB. The changing landscape of secondary ITP: introduction. Semin Hematol. 2009;46(1 Suppl 2):S1.
10. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med. 2001;344(18):1402-1403.
11. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167-3172.
12. Keefe PJ, McGuinn CE, Bussel JB. Randomized double-blind study of increasing doses of eltrombopag in patients with chronic ITP. 57th ASH Meeting, Orlando, FL. Available at: https://ash.confex.com/ash/2015/webprogram/Paper83246.html. Accessed June 29, 2016.
13. Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625-630.
14. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19-25.
15. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223-228.
16. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29-31.
17. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114(1):121-125.
18. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482-1485.
19. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol. 2008;143(1):16-26.
20. Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011;117(21):5723-5732.
21. Stasi R. The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs. Blood. 2011;117(21):5553-5554.
22. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782-4790.
23. Ruggeri M, Tosetto A, Palandri F, et al; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12(8):1266-1273.
24. Nguyen TT, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Saf. 2015;38(12):1179-1186.